What are the approved indications for duloxetine (Cymbalta)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Duloxetine Used For?

Duloxetine (Cymbalta) is FDA-approved for treating major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (including chronic low back pain and osteoarthritis). 1

FDA-Approved Indications

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) with the following approved uses:

Psychiatric Conditions

  • Major Depressive Disorder (MDD): Established efficacy in four short-term and one maintenance trial in adults 1
  • Generalized Anxiety Disorder (GAD): Proven effective in three short-term and one maintenance trial in adults; notably, duloxetine is the only SNRI with FDA approval for GAD in children and adolescents aged 7 years and older 2, 1

Pain Conditions

  • Diabetic Peripheral Neuropathic Pain (DPNP): First-line pharmacologic treatment recommended at 60-120 mg/day, showing consistent efficacy with sustained effectiveness for 1 year 3, 4, 1
  • Fibromyalgia: Effective at 60 mg once daily, improving both pain and quality of life 3, 1
  • Chronic Musculoskeletal Pain: Specifically established for chronic low back pain and chronic pain due to osteoarthritis, with small to moderate benefits (0.60-0.79 point reduction on 0-10 pain scale) 5, 6, 1

Clinical Positioning by Condition

For Neuropathic Pain

Duloxetine is recommended as a first-line medication alongside tricyclic antidepressants, gabapentin, and pregabalin 7, 3. The standard dosing is 30 mg once daily for 1 week, then increase to 60 mg once daily (maximum 60 mg twice daily) 7. An adequate trial requires 4 weeks at therapeutic dose 7.

Key advantage: Unlike tricyclic antidepressants, duloxetine does not produce clinically important electrocardiographic or blood pressure changes, and aminotransferase monitoring is unnecessary 7.

For Anxiety Disorders in Children/Adolescents

Duloxetine stands out as the only SNRI with pediatric FDA approval for GAD in patients ≥7 years old 2. It can be considered for social anxiety, generalized anxiety, separation anxiety, and panic disorders in the 6-18 age group 2.

For Chronic Low Back Pain

When nonpharmacologic approaches (like exercise) provide insufficient relief, duloxetine shows small improvements with mean differences of 0.58-0.74 points on pain scales 6. Use 60 mg/day as the starting therapeutic dose 5, 6.

For Osteoarthritis

Duloxetine demonstrates small to moderate benefits for pain and function, with evidence showing greater effectiveness in patients >65 years and those with knee osteoarthritis specifically 5. Consider it when topical NSAIDs are insufficient or when multiple joints are affected 5.

Common Pitfalls and Caveats

Nausea management: The most common adverse effect is nausea, which can be mitigated by starting at 30 mg once daily for 1 week before increasing to 60 mg 7

Hepatic concerns: Duloxetine has been associated with hepatic failure (rare). Discontinue immediately if jaundice, abdominal pain, hepatomegaly, or elevated transaminases develop 2

Severe skin reactions: Stop duloxetine at first appearance of blisters, peeling rash, mucosal erosions, or signs of Stevens-Johnson syndrome 2

Drug interactions: Avoid concomitant use with MAOIs (serotonin syndrome risk) and CYP1A2 inhibitors like fluvoxamine (which increases duloxetine exposure by 460%) 2

Discontinuation: Taper slowly to avoid withdrawal syndrome 2

Monitoring requirements: Track height, weight, pulse, and blood pressure; no routine laboratory tests needed 2

Contraindications: Avoid in patients with creatinine clearance <30 mL/min or hepatic impairment 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.